Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Support Care Cancer. 2021 Jul;29(7):3783-3792. doi: 10.1007/s00520-020-05902-2. Epub 2020 Nov 24.
Patients, who discontinue early, do not benefit from phase I/II clinical trials (early-phase clinical trials (EPCT)). In this study, associations between objective smartphone measurements of physical activity and fitness and early trial discontinuation in patients with cancer participating in EPCT were investigated.
Before start of treatment, physical activity (steps/day) and physical fitness (meters walked in 6 min) were measured with a smartphone, and patient-reported physical function (PRO-PF) was assessed (EORTC QLQ-C30-PF). Early trial discontinuation was defined as discontinuation ≤ 28 days. Univariable logistic regression analyses were performed to study associations of physical activity, fitness, and function with early trial discontinuation. Optimal cutoff values of physical activity and fitness were assessed with ROCs, based on positive predictive values (PPV).
Median (interquartile range (IQR)) step count was 4263 (2548-6897) steps/day, mean ± standard deviation 6-min walking distance was 477 ± 120 m and median (IQR) PRO-PF score was 83 (67-95) points. Fourteen patients (12%) discontinued the trial early. Smartphone measurements of physical activity in units of 100 steps per day (odds ratio (OR) = 0.96, 95% CI = 0.94-0.99, p = 0.01), physical fitness (OR = 0.99, 95% CI = 0.98-0.99, p < 0.01), and PRO-PF (OR = 0.97, 95% CI = 0.94-1.00, p = 0.03) were associated with early trial discontinuation. Optimal cutoff values were < 900 steps for physical activity and < 285 m for physical fitness. PPV for early trial discontinuation was 100% in patients who walked both < 1500 steps per day and < 300 m in 6 min.
Objective smartphone measurements of physical activity and fitness are associated with early trial discontinuation. However, cutoff values should be externally validated in a larger cohort before implementation in clinical practice.
提前退出的患者无法从 I/II 期临床试验(早期临床试验(EPCT))中获益。本研究旨在探讨癌症患者参与 EPCT 时,智能手机测量的身体活动和体能的客观指标与提前退出试验之间的关系。
在开始治疗之前,使用智能手机测量身体活动(步数/天)和体能(6 分钟步行距离),并评估患者报告的身体功能(EORTC QLQ-C30-PF)。提前退出试验的定义为≤28 天退出。使用单变量逻辑回归分析研究身体活动、体能和功能与提前退出试验之间的关系。根据阳性预测值(PPV),使用 ROC 评估身体活动和体能的最佳截断值。
中位数(四分位距(IQR))步数为 4263(2548-6897)步/天,平均±标准差 6 分钟步行距离为 477±120 m,中位数(IQR)PRO-PF 评分为 83(67-95)分。14 名患者(12%)提前退出试验。以 100 步/天为单位的身体活动智能手机测量值(比值比(OR)=0.96,95%CI=0.94-0.99,p=0.01)、体能(OR=0.99,95%CI=0.98-0.99,p<0.01)和 PRO-PF(OR=0.97,95%CI=0.94-1.00,p=0.03)与提前退出试验有关。最佳截断值为身体活动<900 步和体能<285 m。每天行走步数<1500 步且 6 分钟内行走距离<300 m 的患者提前退出试验的 PPV 为 100%。
智能手机测量的身体活动和体能与提前退出试验有关。然而,在将这些截断值应用于临床实践之前,应该在更大的队列中进行外部验证。